EUVIMEDEUVIMED entdecken
Crossref

Identification of Potent Leucine‐Rich Repeat Kinase 2 Inhibitors by Virtual Screening and Biological Evaluation

Hualiang Shen, Guoqi Yu, Tao Cai, Kai Hu, Tianbo Shang, Yanjuan Luo, Jiawei Zhu, Xiaoxue Bai, Yicheng Xiong, Meiyang Xi iD, Runpu Shen

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Hualiang Shen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Engineering Research Center of Fat-Soluble Vitamin, Shaoxing University, Shaoxing, China. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Protein Kinase Inhibitors, Molecular Docking Simulation, Molecular Dynamics Simulation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson's disease (PD) is the second most common neurodegenerative disease but has limited medications. Targeting leucine‐rich repeat kinase 2 (LRRK2) has been identified as a potential strategy for the treatment of PD. The development of LRRK2 inhibitors has attracted much interest, and various compounds have been reported with significant improvement in preclinical and clinical models. Currently, no LRRK2 inhibitor has been approved for PD intervention. Herein, we reported a virtual screening (VS) workflow combining molecular docking and molecular dynamics (MD) simulations to achieve eight compounds for further enzymatic assay. The results indicated a potent LRRK2 inhibitor 2 with IC 50 values of 2.396 and 5.996 μM against LRRK2 and LRRK2 G2019S, respectively, implying the reliability of this VS approach. Combined with predicted favorable drug‐like properties, this hit can be used as a starting point for further structural optimization, probably offering insight into targeting LRRK2 for PD treatment in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Protein Kinase InhibitorsMolecular Docking SimulationMolecular Dynamics SimulationHumansParkinson DiseaseDrug Evaluation, PreclinicalBinding Sites

Stichwörter der Autor:innen

dockinginhibitory activityleucine‐rich repeat kinase 2 (LRRK2)molecular dynamics (MD) simulationsvirtual screening (VS)

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Protein Kinase InhibitorsLRRK2 protein, human

Autor:innen und Institutionen

  • Zhejiang Engineering Research Center of Fat-Soluble Vitamin, Shaoxing University, Shaoxing, China.
  • School of Chemistry and Chemical Engineering, Shaoxing University, Shaoxing, China.
  • School of Medicine, Shaoxing University, Shaoxing, China.
  • Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, China.

ORCID-Profile: Meiyang Xi

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Shen, H., Yu, G., Cai, T., Hu, K., Shang, T., Luo, Y., Zhu, J., Bai, X., Xiong, Y., Xi, M., & Shen, R. (2025). Identification of Potent Leucine‐Rich Repeat Kinase 2 Inhibitors by Virtual Screening and Biological Evaluation. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70082

Vancouver

Shen H, Yu G, Cai T, Hu K, Shang T, Luo Y, et al. Identification of Potent Leucine‐Rich Repeat Kinase 2 Inhibitors by Virtual Screening and Biological Evaluation. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70082

BibTeX
@article{Shen2025,
  author = {Shen, Hualiang and Yu, Guoqi and Cai, Tao and Hu, Kai and Shang, Tianbo and Luo, Yanjuan and Zhu, Jiawei and Bai, Xiaoxue and Xiong, Yicheng and Xi, Meiyang and Shen, Runpu},
  title = {Identification of Potent Leucine‐Rich Repeat Kinase 2 Inhibitors by Virtual Screening and Biological Evaluation},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70082}
}
Kostenlos starten →